Top 5 Health Care Startup Investors in Isle of Man (August 2026)

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Investment focus

Industry: Biotechnology, Food and Beverage, Health Care
Stage:Series A, Seed
Geography: United States, United Kingdom, Israel

Investor stats

Total investments: 32
Round size: Seed $536k–$20M; Series A $4.6M–$47M
Lead/follow: 41% lead, 59% follow

Portfolio highlights

Netwealth — Netwealth provides expert investment management and tailored wealth planning solutions, helping you confidently achieve your financial goals.
Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Repair Biotechnologies — Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling humanbeings to improve their health span through targeting the causes of age-related diseases and ageing itself.

Show all investments...

We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.

Investment focus

Industry: Biotechnology, Health Care, Therapeutics
Stage:Series B, Series C, Series A
Geography: United States, United Kingdom, China

Investor stats

Total investments: 195
Round size: Series A $22M–$165M; Series B $25M–$140M; Series C $38M–$270M
Lead/follow: 31% lead, 69% follow
Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

Stepful — New York City, 100% Job Guarantee, Online, 4 months, Part-Time, $166 per month
Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.

Show all investments...

We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Investment focus

Industry: Biotechnology, Pharmaceutical, Health Care
Stage:Series A, Seed
Geography: United States, Hong Kong, Isle of Man

Investor stats

Total investments: 14
Round size: Series A $3M–$19M
Lead/follow: 36% lead, 64% follow

Portfolio highlights

LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
Morphoceuticals — Reprogramming the Software of Life: Understanding the bioelectric network that controls tissue repair and organ regeneration
MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.

Show all investments...

Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.

Investment focus

Industry: Biotechnology, Pharmaceutical, Health Care
Stage:Series A, Post-IPO Equity, Seed
Geography: United States, Isle of Man

Investor stats

Total investments: 10
Round size: Series A $3M–$19M; Post-IPO Equity $15M–$80M
Lead/follow: 50% lead, 50% follow

Portfolio highlights

Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Serina Therapeutics — Serina Therapeutics is a biotech company focused on polymer technology to improve how small molecule therapeutics behave in the body
Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

Show all investments...